Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
64
IOBCF Quote, Financials, Valuation and Earnings
Last price:
$13.25
Seasonality move
:
7.45%
Day range:
$13.25 - $13.25
52-week range:
$10.15 - $15.18
Dividend yield:
2.09%
P/E ratio:
21.13x
P/S ratio:
0.60x
P/B ratio:
4.24x
Volume:
200
Avg. volume:
108
1-year change:
-10.89%
Market cap:
$387.8M
Revenue:
$538.9M
EPS (TTM):
$0.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IOBCF
Ion Beam Applications SA
|
-- | -- | -- | -- | -- |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- | -- | -- |
|
GLPG
Galapagos NV
|
$80.4M | -$0.33 | -0.12% | 223.23% | $27.45 |
|
MDXH
MDxHealth SA
|
$28M | -$0.26 | 23% | -35.9% | $7.0400 |
|
NYXH
Nyxoah SA
|
$2.3M | -$0.65 | 198.31% | -26.1% | $11.23 |
|
UCBJY
UCB SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IOBCF
Ion Beam Applications SA
|
$13.25 | -- | $387.8M | 21.13x | $0.28 | 2.09% | 0.60x |
|
CLYYF
Celyad Oncology SA
|
$0.18 | -- | $7.5M | -- | $0.00 | 0% | 37.01x |
|
GLPG
Galapagos NV
|
$31.59 | $27.45 | $2.1B | 21.30x | $0.00 | 0% | 6.57x |
|
MDXH
MDxHealth SA
|
$3.6000 | $7.0400 | $178.2M | -- | $0.00 | 0% | 1.72x |
|
NYXH
Nyxoah SA
|
$4.89 | $11.23 | $210.4M | -- | $0.00 | 0% | 29.02x |
|
UCBJY
UCB SA
|
$144.05 | -- | $54.7B | 38.71x | $0.79 | 0.55% | 7.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IOBCF
Ion Beam Applications SA
|
26.43% | 1.363 | -- | 0.57x |
|
CLYYF
Celyad Oncology SA
|
-- | 0.910 | -- | -- |
|
GLPG
Galapagos NV
|
0.31% | 0.077 | 0.39% | 8.44x |
|
MDXH
MDxHealth SA
|
110.38% | 2.496 | 38.19% | 0.98x |
|
NYXH
Nyxoah SA
|
29.34% | 3.060 | 14.4% | 1.22x |
|
UCBJY
UCB SA
|
21.7% | 0.945 | -- | 1.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IOBCF
Ion Beam Applications SA
|
-- | -- | 6.78% | 8.22% | -- | -- |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- | -- | -- | -- |
|
GLPG
Galapagos NV
|
$70.5M | -$56.2M | -16.42% | -16.48% | -67.61% | -$63.6M |
|
MDXH
MDxHealth SA
|
$16.6M | -$3.5M | -39.3% | -548.42% | -12.67% | -$1M |
|
NYXH
Nyxoah SA
|
-$288.6K | -$28.5M | -76.64% | -96.48% | -1238.32% | -$25M |
|
UCBJY
UCB SA
|
-- | -- | 10.75% | 13.88% | -- | -- |
Ion Beam Applications SA vs. Competitors
-
Which has Higher Returns IOBCF or CLYYF?
Celyad Oncology SA has a net margin of -- compared to Ion Beam Applications SA's net margin of --. Ion Beam Applications SA's return on equity of 8.22% beat Celyad Oncology SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBCFIon Beam Applications SA-- -- $131.5M CLYYFCelyad Oncology SA-- -- -- -
What do Analysts Say About IOBCF or CLYYF?
Ion Beam Applications SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Ion Beam Applications SA has higher upside potential than Celyad Oncology SA, analysts believe Ion Beam Applications SA is more attractive than Celyad Oncology SA.
Company Buy Ratings Hold Ratings Sell Ratings IOBCFIon Beam Applications SA0 0 0 CLYYFCelyad Oncology SA0 0 0 -
Is IOBCF or CLYYF More Risky?
Ion Beam Applications SA has a beta of 1.124, which suggesting that the stock is 12.39% more volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.796%.
-
Which is a Better Dividend Stock IOBCF or CLYYF?
Ion Beam Applications SA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.09%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ion Beam Applications SA pays 53.12% of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend. Ion Beam Applications SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IOBCF or CLYYF?
Ion Beam Applications SA quarterly revenues are --, which are smaller than Celyad Oncology SA quarterly revenues of --. Ion Beam Applications SA's net income of -- is lower than Celyad Oncology SA's net income of --. Notably, Ion Beam Applications SA's price-to-earnings ratio is 21.13x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ion Beam Applications SA is 0.60x versus 37.01x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBCFIon Beam Applications SA0.60x 21.13x -- -- CLYYFCelyad Oncology SA37.01x -- -- --
-
Which has Higher Returns IOBCF or GLPG?
Galapagos NV has a net margin of -- compared to Ion Beam Applications SA's net margin of -286.67%. Ion Beam Applications SA's return on equity of 8.22% beat Galapagos NV's return on equity of -16.48%.
Company Gross Margin Earnings Per Share Invested Capital IOBCFIon Beam Applications SA-- -- $131.5M GLPGGalapagos NV84.76% -$3.58 $2.9B -
What do Analysts Say About IOBCF or GLPG?
Ion Beam Applications SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of $27.45 which suggests that it could fall by -13.07%. Given that Galapagos NV has higher upside potential than Ion Beam Applications SA, analysts believe Galapagos NV is more attractive than Ion Beam Applications SA.
Company Buy Ratings Hold Ratings Sell Ratings IOBCFIon Beam Applications SA0 0 0 GLPGGalapagos NV0 3 1 -
Is IOBCF or GLPG More Risky?
Ion Beam Applications SA has a beta of 1.124, which suggesting that the stock is 12.39% more volatile than S&P 500. In comparison Galapagos NV has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.495%.
-
Which is a Better Dividend Stock IOBCF or GLPG?
Ion Beam Applications SA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.09%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ion Beam Applications SA pays 53.12% of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend. Ion Beam Applications SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IOBCF or GLPG?
Ion Beam Applications SA quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $83.2M. Ion Beam Applications SA's net income of -- is lower than Galapagos NV's net income of -$238.4M. Notably, Ion Beam Applications SA's price-to-earnings ratio is 21.13x while Galapagos NV's PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ion Beam Applications SA is 0.60x versus 6.57x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBCFIon Beam Applications SA0.60x 21.13x -- -- GLPGGalapagos NV6.57x 21.30x $83.2M -$238.4M
-
Which has Higher Returns IOBCF or MDXH?
MDxHealth SA has a net margin of -- compared to Ion Beam Applications SA's net margin of -29.2%. Ion Beam Applications SA's return on equity of 8.22% beat MDxHealth SA's return on equity of -548.42%.
Company Gross Margin Earnings Per Share Invested Capital IOBCFIon Beam Applications SA-- -- $131.5M MDXHMDxHealth SA60.43% -$0.16 $79.6M -
What do Analysts Say About IOBCF or MDXH?
Ion Beam Applications SA has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 95.56%. Given that MDxHealth SA has higher upside potential than Ion Beam Applications SA, analysts believe MDxHealth SA is more attractive than Ion Beam Applications SA.
Company Buy Ratings Hold Ratings Sell Ratings IOBCFIon Beam Applications SA0 0 0 MDXHMDxHealth SA6 0 0 -
Is IOBCF or MDXH More Risky?
Ion Beam Applications SA has a beta of 1.124, which suggesting that the stock is 12.39% more volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.
-
Which is a Better Dividend Stock IOBCF or MDXH?
Ion Beam Applications SA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.09%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ion Beam Applications SA pays 53.12% of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend. Ion Beam Applications SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IOBCF or MDXH?
Ion Beam Applications SA quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $27.4M. Ion Beam Applications SA's net income of -- is lower than MDxHealth SA's net income of -$8M. Notably, Ion Beam Applications SA's price-to-earnings ratio is 21.13x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ion Beam Applications SA is 0.60x versus 1.72x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBCFIon Beam Applications SA0.60x 21.13x -- -- MDXHMDxHealth SA1.72x -- $27.4M -$8M
-
Which has Higher Returns IOBCF or NYXH?
Nyxoah SA has a net margin of -- compared to Ion Beam Applications SA's net margin of -1195.73%. Ion Beam Applications SA's return on equity of 8.22% beat Nyxoah SA's return on equity of -96.48%.
Company Gross Margin Earnings Per Share Invested Capital IOBCFIon Beam Applications SA-- -- $131.5M NYXHNyxoah SA-12.52% -$0.74 $84.7M -
What do Analysts Say About IOBCF or NYXH?
Ion Beam Applications SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 129.58%. Given that Nyxoah SA has higher upside potential than Ion Beam Applications SA, analysts believe Nyxoah SA is more attractive than Ion Beam Applications SA.
Company Buy Ratings Hold Ratings Sell Ratings IOBCFIon Beam Applications SA0 0 0 NYXHNyxoah SA3 1 0 -
Is IOBCF or NYXH More Risky?
Ion Beam Applications SA has a beta of 1.124, which suggesting that the stock is 12.39% more volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IOBCF or NYXH?
Ion Beam Applications SA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.09%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ion Beam Applications SA pays 53.12% of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend. Ion Beam Applications SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IOBCF or NYXH?
Ion Beam Applications SA quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $2.3M. Ion Beam Applications SA's net income of -- is lower than Nyxoah SA's net income of -$27.6M. Notably, Ion Beam Applications SA's price-to-earnings ratio is 21.13x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ion Beam Applications SA is 0.60x versus 29.02x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBCFIon Beam Applications SA0.60x 21.13x -- -- NYXHNyxoah SA29.02x -- $2.3M -$27.6M
-
Which has Higher Returns IOBCF or UCBJY?
UCB SA has a net margin of -- compared to Ion Beam Applications SA's net margin of --. Ion Beam Applications SA's return on equity of 8.22% beat UCB SA's return on equity of 13.88%.
Company Gross Margin Earnings Per Share Invested Capital IOBCFIon Beam Applications SA-- -- $131.5M UCBJYUCB SA-- -- $14.5B -
What do Analysts Say About IOBCF or UCBJY?
Ion Beam Applications SA has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Ion Beam Applications SA has higher upside potential than UCB SA, analysts believe Ion Beam Applications SA is more attractive than UCB SA.
Company Buy Ratings Hold Ratings Sell Ratings IOBCFIon Beam Applications SA0 0 0 UCBJYUCB SA0 0 0 -
Is IOBCF or UCBJY More Risky?
Ion Beam Applications SA has a beta of 1.124, which suggesting that the stock is 12.39% more volatile than S&P 500. In comparison UCB SA has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.475%.
-
Which is a Better Dividend Stock IOBCF or UCBJY?
Ion Beam Applications SA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.09%. UCB SA offers a yield of 0.55% to investors and pays a quarterly dividend of $0.79 per share. Ion Beam Applications SA pays 53.12% of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IOBCF or UCBJY?
Ion Beam Applications SA quarterly revenues are --, which are smaller than UCB SA quarterly revenues of --. Ion Beam Applications SA's net income of -- is lower than UCB SA's net income of --. Notably, Ion Beam Applications SA's price-to-earnings ratio is 21.13x while UCB SA's PE ratio is 38.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ion Beam Applications SA is 0.60x versus 7.52x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBCFIon Beam Applications SA0.60x 21.13x -- -- UCBJYUCB SA7.52x 38.71x -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
